Allysta is dedicated to developing innovative new medicines for unmet needs directed towards novel first-in-class targets.
We proceed from the principle that breakthrough therapies have the greatest chance of success when they are built upon a strong scientific foundation.
We seek to be science-driven and results-focused.
Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical company. We are developing first-in-class therapeutic peptides that uniquely target adiponectin signaling pathways. Adiponectin, a unique cytokine protein, has multiple beneficial actions, including anti-inflammatory, anti-fibrotic, cell regenerative, and beneficial metabolic properties that provides development opportunities in multiple diseases. Our lead drug, ALY688 Ophthalmic Solution, is a topical eye drop for treatment of inflammatory ocular surface disorders, particularly dry eye disease. We have shown that ALY688's anti-inflammatory and cell regenerative actions very effectively reduces inflammation and enhances corneal cell repair. Allysta has also developed a sustained release formulation of ALY688 (ALY688-SR) ideally suited for for systemic administration and we are targeting inflammatory and fibrotic diseases such as NASH (non-alcoholic steatohepatitis), where the multimodal actions of adiponectin activation are ideally suited.
Ocular Surface Inflammation
Developing Innovative Medicines